-
1.发明授权Propylcarbamate derivatives as inhibitors of serine and cysteine proteases 失效丙基氨基甲酸酯衍生物作为丝氨酸和半胱氨酸蛋白酶的抑制剂公开(公告)号：US07288541B2
公开(公告)日：2007-10-30
申请号：US10492059
申请日：2002-10-02
IPC分类号： A61K31/535 , A61K31/415 , A61K31/44 , C07D417/00 , C07D401/00
CPC分类号： C07D231/12 , C07D233/56 , C07D249/08 , C07D401/12 , C07D401/14 , C07D417/12 , C07D417/14
摘要： The present invention includes ketone derivatives (I) and (II), which are useful as cathepsin K inhibitors. The described invention also includes methods of making such ketone derivatives as well as methods of using the same in the treatment of disorders, including osteoporosis
摘要翻译： 本发明包括可用作组织蛋白酶K抑制剂的酮衍生物（I）和（II）。 所述的发明还包括制备这样的酮衍生物的方法以及使用该酮衍生物的方法来治疗疾病，包括骨质疏松症
-
公开(公告)号：US20100249179A1
公开(公告)日：2010-09-30
申请号：US12663722
申请日：2008-06-13
IPC分类号： A61K31/4365 , C07D497/04 , A61P1/16 , C07D413/12 , A61K31/422 , C07D413/14 , A61K31/4439 , A61K31/423
CPC分类号： C07D413/12 , C07D261/08 , C07D413/14 , C07D495/04
摘要： The present invention provides novel isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.
摘要翻译： 本发明提供新的异恶唑化合物，药物组合物，治疗用途及其制备方法。
-
公开(公告)号：US06455507B1
公开(公告)日：2002-09-24
申请号：US09424934
申请日：2000-03-17
申请人： John Charles Drach , Leroy B. Townsend , Frank Leslie Boyd, Jr. , Stanley Dawes Chamberlain , Susan Mary Daluge , David Norman Deaton , Marc W. Andersen , George Andrew Freeman
发明人： John Charles Drach , Leroy B. Townsend , Frank Leslie Boyd, Jr. , Stanley Dawes Chamberlain , Susan Mary Daluge , David Norman Deaton , Marc W. Andersen , George Andrew Freeman
IPC分类号： A61K3170
CPC分类号： C07D235/24 , C07D235/30 , C07D405/04 , C07H19/052
摘要： Benzimidazole derivatives useful for treating or preventing viral infections such as those caused by herpes viruses or in the treatment of restenosis following surgical techniques. Methods of preparing these benzimidazole derivatives and pharmaceutical compositions containing them are described.
摘要翻译： 用于治疗或预防病毒感染的苯并咪唑衍生物，例如由疱疹病毒引起的那些或在手术技术后治疗再狭窄。 描述制备这些苯并咪唑衍生物的方法和含有它们的药物组合物。
-
公开(公告)号：US08158665B2
公开(公告)日：2012-04-17
申请号：US12720023
申请日：2010-03-09
申请人： Richard Caldwell , David Norman Deaton , Robert Blount McFadyen , Frank Navas, III , Paul Kenneth Spearing
发明人： Richard Caldwell , David Norman Deaton , Robert Blount McFadyen , Frank Navas, III , Paul Kenneth Spearing
IPC分类号： A61K31/42
CPC分类号： C07D413/12 , C07D261/08
摘要： The present invention provides novel substituted isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.
-
公开(公告)号：US20110034507A1
公开(公告)日：2011-02-10
申请号：US12665772
申请日：2008-06-13
IPC分类号： A61K31/4725 , C07D413/12 , C07D417/14 , C07D413/14 , C07D409/12 , C07D417/12 , C07D413/06 , A61K31/422 , A61K31/427 , A61K31/4439 , A61K31/428 , A61K31/423 , A61P3/00 , A61P1/16 , A61P35/00
CPC分类号： C07D413/12 , C07D261/08 , C07D413/06 , C07D413/14 , C07D417/12 , C07D417/14
摘要： The present invention relates to farnesoid X receptors (FXR, NR1H4). FXR is a member of the nuclear receptor class of ligand-activate transcription factors. More particularly, the present invention relates to compounds useful as agonists for FXR, pharmaceutical formulations comprising such compounds, and therapeutic use of the same. Novel isoxazole compounds are disclosed as part of pharmaceutical compositions for the treatment of a condition mediated by decreased FXR activity, such as obesity, diabetes, cholestatic liver disease, liver fibrosis, and metabolic syndrome.
摘要翻译： 本发明涉及法呢酯X受体（FXR，NR1H4）。 FXR是配体 - 激活转录因子核受体类的成员。 更具体地说，本发明涉及可用作FXR激动剂的化合物，包含这些化合物的药物制剂及其治疗用途。 公开了新的异恶唑化合物作为用于治疗由FXR活性降低（如肥胖，糖尿病，胆汁淤积性肝病，肝纤维化和代谢综合征）介导的病症的药物组合物的一部分。
-
公开(公告)号：US20100160398A1
公开(公告)日：2010-06-24
申请号：US12720023
申请日：2010-03-09
申请人： Richard Caldwell , David Norman Deaton , Robert Blount McFadyen , Frank Navas, III , Paul Kenneth Spearing
发明人： Richard Caldwell , David Norman Deaton , Robert Blount McFadyen , Frank Navas, III , Paul Kenneth Spearing
CPC分类号： C07D413/12 , C07D261/08
摘要： The present invention provides novel substituted isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.
摘要翻译： 本发明提供了新的取代的异恶唑化合物，药物组合物，治疗用途及其制备方法。
-
公开(公告)号：US20100120775A1
公开(公告)日：2010-05-13
申请号：US12446594
申请日：2007-10-23
申请人： Jonathan York Bass, III , David Norman Deaton , Justin Caravella , Robert Blount McFadyen , Frank Navas, III , Paul Kenneth Spearing
发明人： Jonathan York Bass, III , David Norman Deaton , Justin Caravella , Robert Blount McFadyen , Frank Navas, III , Paul Kenneth Spearing
IPC分类号： A61K31/498 , C07D215/20 , A61K31/47 , C07D413/02 , A61K31/517 , C07D241/36 , A61P3/04 , A61P3/10 , A61P1/16
CPC分类号： C07D413/14 , C07D413/12
摘要： The present invention provides novel substituted isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.
-
公开(公告)号：US20080167356A1
公开(公告)日：2008-07-10
申请号：US11609914
申请日：2006-12-13
申请人： Richard CALDWELL , David Norman Deaton , Robert Blount McFayden , Frank Navas , Paul Kenneth Spearing
发明人： Richard CALDWELL , David Norman Deaton , Robert Blount McFayden , Frank Navas , Paul Kenneth Spearing
IPC分类号： A61K31/42 , C07D261/06 , A61P3/00 , A61P5/00
CPC分类号： C07D413/12 , C07D261/08
摘要： The present invention provides novel substituted isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.
摘要翻译： 本发明提供了新的取代的异恶唑化合物，药物组合物，治疗用途及其制备方法。
-
公开(公告)号：US06172064B2
公开(公告)日：2001-01-09
申请号：US09382333
申请日：1999-08-25
申请人： Robert Carl Andrews , Marc Werner Andersen , David John Cowan , David Norman Deaton , Scott Howard Dickerson , David Harold Drewry , Michael David Gaul , Michael Joseph Luzzio , Brian Edward Marron , Michael Howard Rabinowitz
发明人： Robert Carl Andrews , Marc Werner Andersen , David John Cowan , David Norman Deaton , Scott Howard Dickerson , David Harold Drewry , Michael David Gaul , Michael Joseph Luzzio , Brian Edward Marron , Michael Howard Rabinowitz
IPC分类号： C07D21170
CPC分类号： C07D213/40 , C07C259/06 , C07D295/13 , C07D333/24
摘要： A family of compounds having the general structural formula where W is a reverse hydroxamic acid group, and R1, R2, R3, R4, R5 and R6 are as described in the specification, or a pharmaceutically acceptable salt, solvate, biohydrolyzable ester, biohydrolyzable amide, affinity reagent, or prodrug thereof. Also described are methods for their preparation, pharmaceutical compositions including such compounds and their use in medicine.
摘要翻译： 具有通式结构式W的化合物族是反向异羟肟酸基团，R 1，R 2，R 3，R 4，R 5和R 6如说明书中所述，或其药学上可接受的盐，溶剂化物，生物可水解的酯，可生物水解的酰胺， 亲和试剂或其前药。 还描述了它们的制备方法，包括这些化合物的药物组合物及其在药物中的用途。
-
公开(公告)号：US07960552B2
公开(公告)日：2011-06-14
申请号：US11876906
申请日：2007-10-23
申请人： Jonathan York Bass, III , Justin Caravella , David Norman Deaton , Robert Blount McFadyen , Frank Navas, III , Paul Kenneth Spearing
发明人： Jonathan York Bass, III , Justin Caravella , David Norman Deaton , Robert Blount McFadyen , Frank Navas, III , Paul Kenneth Spearing
IPC分类号： C07D401/00
CPC分类号： C07D413/14 , C07D413/12
摘要： The present invention provides novel substituted isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.
摘要翻译： 本发明提供了新的取代的异恶唑化合物，药物组合物，治疗用途及其制备方法。
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.025 秒)
